Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MURANASDAQ:NBRVNASDAQ:NERVNASDAQ:QNCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMURAMural Oncology$2.56-3.8%$2.41$0.95▼$4.74$44.21M3.911.30 million shs75,867 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs23 shsNERVMinerva Neurosciences$1.54-5.6%$1.62$1.15▼$3.69$10.76M-0.528,231 shs5,264 shsQNCXQuince Therapeutics$0.84-11.4%$1.18$0.51▼$2.45$37.13M0.83283,849 shs478,293 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMURAMural Oncology-3.76%+1.19%+148.54%-39.91%-34.69%NBRVNabriva Therapeutics0.00%0.00%0.00%+4,900.00%+4,900.00%NERVMinerva Neurosciences-5.62%-4.74%-1.87%-24.96%-37.97%QNCXQuince Therapeutics-11.43%-19.10%-17.51%-40.75%-7.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMURAMural Oncology2.3021 of 5 stars3.32.00.00.02.01.71.3NBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANERVMinerva Neurosciences3.6359 of 5 stars3.04.00.04.62.90.00.0QNCXQuince Therapeutics2.8989 of 5 stars3.63.00.00.02.11.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMURAMural Oncology 2.60Moderate Buy$13.00407.81% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/ANERVMinerva Neurosciences 2.00Hold$5.00225.01% UpsideQNCXQuince Therapeutics 3.29Buy$8.00850.80% UpsideCurrent Analyst Ratings BreakdownLatest NERV, MURA, NBRV, and QNCX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/25/2025MURAMural OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight3/25/2025MURAMural OncologyRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$18.003/25/2025MURAMural OncologyJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/25/2025QNCXQuince TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $4.003/24/2025QNCXQuince TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$10.003/12/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.002/26/2025NERVMinerva NeurosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMURAMural OncologyN/AN/AN/AN/A$15.81 per shareN/ANBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00NERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/AQNCXQuince TherapeuticsN/AN/AN/AN/A$1.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMURAMural Oncology-$207.45M-$7.58N/AN/AN/AN/A-70.10%-61.30%N/ANBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ANERVMinerva Neurosciences-$30M$0.19N/AN/AN/AN/AN/A-6.74%N/AQNCXQuince Therapeutics-$31.39M-$1.31N/AN/AN/AN/A-53.27%-22.73%N/ALatest NERV, MURA, NBRV, and QNCX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MURAMural Oncology-$1.68-$1.93-$0.25-$1.93N/AN/A5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/A5/13/2025Q1 2025QNCXQuince Therapeutics-$0.24-$0.34-$0.10-$0.34N/AN/A3/24/2025Q4 2024QNCXQuince Therapeutics-$0.19-$0.28-$0.09-$0.28N/A$0.17 million3/11/2025Q4MURAMural Oncology-$1.96-$2.01-$0.05-$2.01N/AN/A2/27/2025Q4 2024NERVMinerva Neurosciences-$1.05-$0.56+$0.49-$0.56N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMURAMural OncologyN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMURAMural OncologyN/A7.387.38NBRVNabriva Therapeutics0.120.850.52NERVMinerva NeurosciencesN/A6.236.23QNCXQuince Therapeutics0.339.539.53Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMURAMural Oncology80.21%NBRVNabriva Therapeutics0.27%NERVMinerva Neurosciences34.56%QNCXQuince Therapeutics30.75%Insider OwnershipCompanyInsider OwnershipMURAMural Oncology0.06%NBRVNabriva Therapeutics1.63%NERVMinerva Neurosciences8.60%QNCXQuince Therapeutics20.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMURAMural Oncology11917.27 million17.01 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableNERVMinerva Neurosciences96.99 million6.39 millionNot OptionableQNCXQuince Therapeutics6044.12 million36.61 millionOptionableNERV, MURA, NBRV, and QNCX HeadlinesRecent News About These CompaniesQuince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 14 at 3:19 AM | finance.yahoo.comQuince Therapeutics (QNCX) to Release Quarterly Earnings on MondayMay 11, 2025 | americanbankingnews.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.00 Average Price Target from BrokeragesMay 10, 2025 | americanbankingnews.comQuince Therapeutics to Present at Citizens Life Sciences ConferenceApril 30, 2025 | businesswire.comQuince Therapeutics to Present at Jones Healthcare and Technology Innovation ConferenceApril 3, 2025 | businesswire.comAnalysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD)March 27, 2025 | markets.businessinsider.comQuince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial ResultsMarch 24, 2025 | businesswire.comOppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform RecommendationMarch 24, 2025 | msn.comQuince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-TelangiectasiaFebruary 7, 2025 | businesswire.comQuince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 5, 2025 | businesswire.comQuince Therapeutics gets USPTO notice of allowance in Ataxia-TelangiectasiaFebruary 4, 2025 | markets.businessinsider.comQuince Therapeutics secures USPTO nod for A-T treatment patentFebruary 4, 2025 | msn.comQuince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-TelangiectasiaFebruary 4, 2025 | businesswire.comQuince Therapeutics Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-TelangiectasiaJanuary 27, 2025 | finance.yahoo.comQuince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory BoardJanuary 24, 2025 | finance.yahoo.comQuince Therapeutics initiated with a Buy at BrooklineDecember 19, 2024 | msn.comBrookline Capital Initiates Coverage of Quince Therapeutics (QNCX) with Buy RecommendationDecember 19, 2024 | msn.comQuince Therapeutics Share Price (QNCX.US)November 18, 2024 | lse.co.ukQuince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | businesswire.comQuince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia ResearchNovember 13, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNERV, MURA, NBRV, and QNCX Company DescriptionsMural Oncology NASDAQ:MURA$2.56 -0.10 (-3.76%) As of 05/14/2025 04:00 PM EasternMural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Minerva Neurosciences NASDAQ:NERV$1.54 -0.09 (-5.62%) As of 05/14/2025 03:49 PM EasternMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Quince Therapeutics NASDAQ:QNCX$0.84 -0.11 (-11.43%) As of 05/14/2025 04:00 PM EasternQuince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
